COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience

COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience

Bibliographic Details
Main Authors:	Mohammad Shahidi-Dadras, Fahimeh Abdollahimajd, Laya Ohadi, Mohammadreza Tabary, Farnaz Araghi, Nikoo Mozafari, Parviz Toosi, Sahar Dadkhahfar
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-02-01
Series:	Journal of Dermatological Treatment
Online Access:	http://dx.doi.org/10.1080/09546634.2020.1789041

Similar Items

Cardiac function in pemphigus vulgaris patients before and after steroid pulse therapy
by: Mohammad Shahidi-Dadras, et al.
Published: (2021-10-01)

Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)?
by: Mohammad Shahidi-Dadras, et al.
Published: (2022-02-01)

Rituximab‐induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review
by: Leila Ghadirzade Arani, et al.
Published: (2024-03-01)

Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study
by: Roja Toosi, et al.
Published: (2021-01-01)

Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?
by: Christian Ciolfi, et al.
Published: (2024-01-01)

Rituximab in the Management of a Child with Pemphigus Vulgaris: Case Study
by: Nikolay N. Murashkin, et al.
Published: (2022-11-01)

Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability
by: Ciolfi C, et al.
Published: (2022-11-01)

Pre-infusion checklist for rituximab in pemphigus vulgaris patients: clinical audit
by: Farah Sagheer, et al.
Published: (2023-07-01)

Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant
by: Giulio Fortuna, et al.
Published: (2021-11-01)

Use of rituximab in pemphigus vulgaris/foliaceus patients during COVID-19 pandemic
by: Inês Aparício-Martins, et al.
Published: (2022-10-01)

Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis.
by: Ashwin Agarwal, et al.
Published: (2018-01-01)

The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study
by: Xingli Zhou, et al.
Published: (2024-12-01)

Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris
by: Zainab A. Jafri, et al.
Published: (2022-04-01)

Rituximab monotherapy in mild pemphigus
by: Ali Nili, et al.
Published: (2022-04-01)

Pemphigus vulgaris
by: Abdullah Mancy
Published: (2021-12-01)

Pemphigus vulgaris
by: Vijeev Vasudevan, et al.
Published: (2008-01-01)

A challenging case of psoriasis flare-up after COVID-19 infection
by: Soheila Nasiri, et al.
Published: (2020-07-01)

Electrocardiographic changes after high-dose corticosteroid pulse therapy in pemphigus patients
by: Mehdi Pishgahi, et al.
Published: (2018-11-01)

Severe Pemphigus Vulgaris Resistant to Conventional Therapies and with Hypersensitivity to Rituximab in a 12-Year-Old Child
by: Maria Beatrice De Felici Del Giudice, et al.
Published: (2023-05-01)

Efficacy and safety of biosimilar rituximab in the treatment of pemphigus vulgaris: a single center experience of 12 cases
by: Federico Bardazzi, et al.
Published: (2022-01-01)

Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus
by: Christina Jiang, BS, MS, et al.
Published: (2023-12-01)

Subtype transition from pemphigus vulgaris to pemphigus foliaceus
by: Ty Gilkey, BS, et al.
Published: (2023-01-01)

Pain management of pemphigus vulgaris
by: Rajesh Kumar Muniandy, et al.
Published: (2022)

Pemphigus vulgaris and koebner phenomenon
by: Hulya Nazik, et al.
Published: (2019-06-01)

The genetic basis of pemphigus vulgaris
by: Dan Vodo, et al.
Published: (2023-06-01)

From the Cochrane Library: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus
by: Ramiro Rodriguez, et al.
Published: (2023-12-01)

Pemphigus vulgaris in a neonate born to a mother with pemphigus vulgaris: A case report
by: Ayush Anand, et al.
Published: (2023-12-01)

Evaluation of the possible association between acantholysis and anti‐desmogleins 1 and 3 values in pemphigus vulgaris and pemphigus foliaceus
by: Maryam Mobarakabadi, et al.
Published: (2019-12-01)

Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris
by: Katharina Boch, et al.
Published: (2022-03-01)

Kaposi's sarcoma in a patient with pemphigus vulgaris mimicking exacerbation of pemphigus
by: Kamran Balighi, et al.
Published: (2023-05-01)

Application of reflectance confocal microscopy in the diagnosis of pemphigus vulgaris and pemphigus foliaceus
by: Marta Kurzeja
Published: (2022-07-01)

A relapse of pemphigus vulgaris in pemphigus herpetiformis or a phenotypic “switch”
by: Siham Belmourida, et al.
Published: (2022-01-01)

Pemphigus vulgaris presenting with epigastric pain
by: Marawan Elmassry, et al.
Published: (2023-05-01)

Risk of atrial fibrillation in pemphigus vulgaris
by: Nastaran Namazi, et al.
Published: (2018-01-01)

A new emergence of pemphigus vulgaris
by: Maryam Moshaverinia, et al.
Published: (2013-06-01)

Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemic
by: Mohammad Shahidi Dadras, et al.
Published: (2022-04-01)

Challenges faced by patients with morphea in the era of SARS-CoV-2
by: Mohammad Shahidi Dadras, et al.
Published: (2022-02-01)

The cutaneous form of pemphigus vulgaris of the pemphigus chancre type: clinical and therapeutic implications
by: Natalia Welc, et al.
Published: (2024-02-01)

How to decrease systemic corticosteroids in pemphigus patients under rituximab
by: Fabrizio Martora, et al.
Published: (2022-07-01)

Is transition between subtypes of pemphigus possible? A series of pemphigus vulgaris patients showing the transition to pemphigus foliaceus
by: Rifkiye Kucukoglu, et al.
Published: (2023-11-01)